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Abstract 
Patients use various sources to obtain infor-
mation on pharmaceutical drugs. Mobile health care 
applications (apps) providing drug information to 
users are increasingly made available and of rising 
importance for the health care domain. However, 
apps usually offer functionality that only medical 
professionals or vendors consider useful for patients, 
although their considerations are not likely to meet 
patient expectations. In our exploratory study, we 
identify 33 features patients expect in apps for drug 
information provision with interviews and empirical-
ly assess their perceived importance in an online 
survey. Results indicate that patients desire personal-
ization features for provided information but not for 
the app interface. This work contributes to research 
and practice by identifying and empirically ranking 
drug information provision features patients find 
important. We furthermore establish a foundation for 
future research on effective mobile drug information 
provision and provide insights for practice on devel-
opment of patient-centered mobile health apps.  
 
 
1. Introduction  
 
Medical professionals should not ask what infor-
mation their patients could provide to them but what 
information they should provide to their patients. 
Dating back to the Hippocratic Oath such behavior 
seems obvious, but today more important than ever. 
A brief look at the current health information systems 
(IS) landscape reveals strong affection for the big 
data hype. Large quantities of personal information 
are merged to pseudonymized profiles that represent 
average needs and demands of all patients and mask 
the needs and demands of the individual patient. 
In contrast, the overall health care domain is un-
dergoing a sweeping shift from paternalism to pa-
tient-centered health care [1]. In the past, health care 
was focused on generalization and the population 
level. Nowadays, patient-centered health care instead 
focuses on patients’ individual needs [2]. Pharmaceu-
tical drugs are used in health care to cure or amelio-
rate symptoms of an illness or a medical condition. 
Lacking drug adherence, contributing to higher 
treatment costs, poor health care outcomes, loss of 
confidence, and higher morbidity and mortality rates, 
is a core issue in health care [3, 4]. Patients can inten-
tionally refuse or unintentionally forget to take pre-
scribed drugs. In the latter case, active reminders can 
familiarize patients with a prescribed regimen, make 
them accustomed to drug taking, and help to reduce 
non-adherence [5], whereas, the former case is often 
caused by a lack of information on drugs [6]. Provi-
sion of information on drugs patients take or intend to 
take is crucial for the success of therapy but seldom 
meets patients’ needs and demands. 
The rapid growth of mobile health information 
technology (IT) as well as the increasing mobile net-
work expansion spurred the development of mobile 
health IS targeting patients. Ubiquitous information 
access, led to a wide spectrum of mobile health IS 
promoting patients’ drug adherence through drug 
information provision features. For instance, online 
drug information databases, acoustic reminders, or 
text messages delivered through smartphone applica-
tions (apps) [7], clearly demonstrate the potential of 
current technology to provide information that pa-
tients demand [5]. However, medical professionals 
and vendors remain the key interest groups. Conse-
quently, information creation and development of 
mobile health IS features for patients is often based 
on requirements, objectives, and expectations of 
medical professionals and vendors. Patients serve 
only as recipients of drug information. Little is 
known on what features patients expect in mobile 
health IS for drug information provision and how 
patients expect these features to help them to improve 
their drug adherence. 
Extant research on evaluation and assessment of 
smartphone health apps for drug adherence is also 
often based on the expectations and demands of in-
terest groups other than patients. Quality benchmarks 
for mobile health IS features (eg, usefulness for pa-
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tients) are usually not based on patients’ but on re-
searchers’ or medical professionals’ expectations [5, 
8–10]. Hence, developers tend to tailor mobile health 
IS offerings to comply with expectations of research-
ers and medical professionals. However, neither med-
ical professionals’ nor researchers’ expectations of 
features to be offered in mobile health IS targeting 
patients are likely to match patients’ actual expecta-
tions, requirements, and demands. Consequently, 
provided drug information is often not understood, of 
no avail to patients, and fails to make an impact on 
patients’ drug adherence. 
To move forward, our research takes a step back 
and investigates the main interest group’s (patients’) 
expectations for features to be offered in mobile 
health IS focused on drug information provision to 
improve patients’ drug adherence. As an exploratory 
study towards better understanding patients’ expecta-
tions for drug provision features, this paper answers 
the following research questions from the patient 
perspective: What features do drug information pro-
vision apps need to offer? What is the relative im-
portance of identified features and what aspects of 
drug adherence are influenced by these features?  
We solicit a study sample of potential users of 
mobile health IS and determine their expectations for 
features to be included in mobile health IS concerned 
with drug information provision. As a first phase, we 
conducted single-person, semi-structured interviews 
with a group of twelve potential users of drug infor-
mation provision apps. The answers were summa-
rized, structured, and grouped. For the second phase, 
208 study participants were recruited with Amazon 
Mechanical Turk (AMT) [11] to find out how poten-
tial users expect the features identified in the first 
phase to impact their state of health, determine the 
importance of each feature, and identify the drug ad-
herence facilitators users perceive to be impacted by 
the respective feature. The drug adherence facilitators 
were derived from the dimensions of a taxonomy of 
health IT and drug adherence [12]. 
Our work contributes to the scientific knowledge 
base by identifying and empirically ranking features 
for mobile drug information provision health IS de-
sired by patients. We furthermore establish a founda-
tion for future research on effective mobile drug in-
formation provision and provide insights for practice 
on development of patient-centered mobile health IS. 
 
2. Related Research 
 
2.1. Drug Information Provision for Patients 
 
In the IS domain, the term ‘information’ refers to 
data associated, structured, and formed to meaningful 
facts [13]. ‘Information’ is used to transfer 
knowledge to a recipient or a group of recipients. 
Communicating information to recipients turns out 
difficult because individuals’ information demands 
and level of expertise vary [14]. Hence, transmitted 
information often cannot be understood or is misin-
terpreted by individual recipients. This results in dif-
ferences in understanding of communicated infor-
mation for different individuals. Such differences in 
understanding are particularly critical in the health 
care domain (eg, for the care provider-patient com-
munication relationship). To enhance comprehensi-
bility of information, the same information must be 
adapted to the demands and expectations of different 
recipients, in order to be meaningful to all possible 
recipients. Adaption can, for example, be based on 
education, qualification, or demographics. Personali-
zation based on individuals’ demands and needs is an 
effective method of adapting information [15]. 
The relevance of information provision in today’s 
health care landscape increases with the rising num-
ber of health IT solutions focusing on information 
provision for patients [16, 17]. Especially user-
centered health IS for patients (patient-centered 
health IS) focus on tailored information provision for 
patients and must be primarily guided by the de-
mands and expectations of patients. Drug information 
serves as a crucial information source for patients. 
However, drug information is created by pharmaceu-
tical companies. Patients cannot affect and are not 
involved in drug information creation or its provision 
process. Yet, they are the most important recipients 
of drug information. This makes provision of tailored 
drug information challenging. 
In contrast to patients, other interest groups can 
exert influence on provided information and on the 
provision process itself to further their objectives. 
Care providers, for instance, may be interested in 
providing as little side effect information as required 
by law to lower patients’ worries and uncertainties 
[18]. In contrast, pharmacists are interested in com-
prehensive drug information provision to reduce pa-
tients' inquiries about missing information [19]. Since 
patients usually do not have a medical education, 
albeit carrying the sole responsibility to comply with 
prescribed regimens, patients require well-crafted 
drug information provision. Current drug information 
provision is however inconsistent, intransparent, con-
tradictory, and contains inappropriate wording and 
technical terms [20]. Expectations for features of 
different interest groups are contradictory, and more 
importance is often given to medical professionals’ 
expectations and demands instead of the require-
ments of patients. Mobile health IS features for drug 
information provision are often only a byproduct of 
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companies’ existing health IS. However, patients’ 
demands need to be considered in effective mobile 
health IS for patients [21]. 
 
2.2. Patient-Centered Health IT 
 
Patient-centered health care is concerned with 
care provision consistent with the values, needs, and 
expectations of patients and is most beneficial when 
medical professionals involve patients in health care 
discussions and decisions [1, 22]. Patient-centered 
health care focuses primarily on the well-being of the 
individual patient instead of the financial wellbeing 
of the overall healthcare industry [23]. Patient-
centeredness implies that actions contributing to 
health care and treatment processes can be initiated 
by patients and decisions are made with patient con-
sultation [24, 25]. Consequently, patients do not feel 
disregarded and have coequal decision-making au-
thority [26]. Patient-centered health care promises a 
number of benefits for all involved interest groups 
[27–29]. When patients consult online health IS, they 
seek for additional information on their treatment 
(eg, in case of dissatisfaction with prescribed treat-
ment plans) and expect to find reasonable advice 
helping to manage their own care [30, 31]. However, 
patients usually do not have sufficient medical exper-
tise to assess the whole picture of their state of health 
and to estimate the consequences of their decisions 
[32]. Hence, medical professionals still must steer 
patients’ decisions and anticipate wrong decisions 
through additional information provision [32, 33]. In 
the end, patients and medical professionals must to-
gether shoulder the greater responsibility that comes 
with the greater decision-making power of pa-
tients [34]. 
Patient involvement in treatment processes can 
proceed in different ways [29, 35]: Patients can pro-
vide additional relevant information about their 
health condition, self-quantification devices can be 
employed to gather vital signs during daily life activi-
ties, or patients can share experiences with a drug or 
a treatment [32]. Shared information strengthens the 
decision process for medical professionals [26]. Pa-
tients’ experiences offer insights and reveal issues 
often not considered during conventional medical 
check-ups [36]. The enhanced information base eases 
longitudinal analyses of patients’ state of health by 
tracking disease courses, symptoms, and recovery 
processes [25, 37]. This allows patients to recognize 
potential issues and to contact medical professionals 
in a timely fashion [27, 29]. Information exchange 
with patients enables medical professionals to get 
new insights into courses of treatment and to avoid 
unforeseen pitfalls with other patients subject to simi-
lar diseases or treatment methods [38]. 
Patient-centered health care is a radical change in 
the very traditional health care domain and has the 
potential to increase patient satisfaction, quality of 
care, and overall outcomes through patient empow-
erment [39], if patients understand the provided in-
formation and if supported by a supportive health IS 
landscape [25, 37]. Health IS, tailoring provided in-
formation to patients’ demands, empower patients to 
comprehend provided information. 
 
2.3. Personalization of Drug Information 
Provision 
 
Patient-centered mobile health IS offerings bear 
the potential to provide patients with tailored infor-
mation. Thus, they must not be guided by one interest 
groups’ demands and expectations and, in particular, 
not only by medical professionals’ demands and ex-
pectations. Mobile health IS allow to offer personali-
zation features that enhance users’ capabilities to 
personalize provided information without offering 
individual information for each patient. Drug infor-
mation can be personalized by hiding undesired or 
irrelevant information, such as pregnancy-related 
information for male users, and emphasizing im-
portant information, such as pregnancy-related in-
formation for pregnant female users. In general, per-
sonalization of information in form of text may be 
based on various factors, such as explicit personal 
details or implicit social environmental profiling [15]. 
Personalization could be automated, based on manu-
ally entered preferences, or rely on general usage 
patterns. In all cases, mobile health IS must offer 
technical assistance for personalization because pa-
tients may not be familiar with the possibilities and 
features offered by technology. Patients’ activities 
must be guided, preventing them to lessen their state 
of health. Instead of offering patients more degrees of 
freedom for personalization, it seems more feasible to 
offer a set of features that do the tailoring of infor-
mation for patients and reduce their effort to person-
alize the desired information. This would facilitate 
provision of drug information, reduce the risk of 
harmful consequences, and does not require costly, 
manual intervention by medical professionals. 
In this research, we assess the information provi-
sion features for patient-centered mobile health IS by 
consolidating patients’ expectations for drug infor-
mation provision features and identifying the ex-
pected impact on patients’ state of health from the 
patient perspective. Involving patients in our research 
is important to determine patients’ viewpoint on fea-
tures to be offered by mobile health IS for drug in-
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formation provision. The obtained catalog of desired 
features can inform future research projects by elicit-
ing patients’ perspectives and enables prioritization 
of important or desired features.  
 
3. Method 
 
Our study is split into a qualitative interview sur-
vey and a quantitative online survey phase. To obtain 
an overview of patients’ expectations for features to 
be offered by mobile drug information provision 
health IS, qualitative, semi-structured, single-person 
interviews were conducted. Semi-structured inter-
views are an effective approach for requirement elici-
tation [40]. The result of the first phase of the study is 
a consolidated list of users’ desired features for mo-
bile drug information provision health IS and serves 
as input for the second study phase. In the second 
phase, users rated the features from phase one ac-
cording to their importance. Furthermore, users were 
asked to judge which drug adherence facilitators are 
impacted by the respective feature. 
 
3.1. Qualitative Survey Phase Design 
 
The interviewees for the initial user survey were 
aware of the domain and topic of the study. The in-
terviews were conducted by one researcher following 
an interview guide. In the beginning, the interviewer 
introduced the domain of health care and explained 
the concept of mobile drug information provision 
health IS and how they are intended to influence drug 
adherence through drug information provision. After 
the introduction, demographics were collected (eg, 
gender, age). In the following a scenario, where in-
terviewees were asked to imagine themselves in a 
situation searching for online drug information, was 
introduced. In essence, participants were asked exact-
ly one main question: “What features can you imag-
ine in a web application for drug information provi-
sion?”. Interviewees were also asked to describe de-
sired features for mobile drug information provision 
health IS. Finally, all mentioned desired features 
were clearly named and described, duplicates were 
removed, and the features were grouped according to 
emerging patterns. Interviews were coded inde-
pendently by two researchers to avoid bias. 
 
3.2. Facilitation of Drug Adherence 
 
To find out how patients perceive the features to 
impact drug adherence in the quantitative survey, we 
derived six drug adherence facilitators from a taxon-
omy of health IT and medication adherence1 [12]. 
The dimensions of the taxonomy indicate which drug 
adherence facilitators are potentially enhanced 
through health IS features. Study participants were 
asked for a binary decision whether in their opinion 
the drug adherence facilitators are affected by the 
respective feature. 
The first drug adherence facilitator is ‘Seamless 
data input’. Ease of data input is crucial for users’ 
future behavior. If users are obliged to perform many 
complex steps to import or enter personal health in-
formation in a mobile health IS, it is unlikely that 
they will use the feature. Easy and intuitive to use 
health IS features lead to increased usage, or usage 
intention, which in turn enables mobile health IS fea-
tures to influence users’ drug adherence. The second 
facilitator is ‘Location- and device-independent ac-
cess’, which in general refers to the ability to make 
use of a mobile health IS feature independent of loca-
tion or technical equipment. If users have the ability 
to make use of mobile health IS features on any de-
vice, mobile health IS use will increase and drug ad-
herence may improve. The third facilitator is ‘Col-
laboration with medical professionals or other us-
ers’. Collaboration between users and medical pro-
fessionals or with other users is referred to: working 
jointly towards a better state of health or better health 
care provision. An ongoing process of sharing infor-
mation with each other and the possibility to benefit 
for both sides from personal experiences or frequent-
ly occurring problems leads to enhanced drug literacy 
and hence to reduced error rate when taking drugs. 
The fourth drug adherence facilitator is ‘Quality con-
trol by medical professionals’. Most health care tasks 
involving mobile health IS can be executed by users 
without the assistance of medical professionals. 
However, some tasks require qualified input from 
medical professionals or other experts (eg, to assess 
blood values). Medical professionals have the highest 
authority in health care and are trained to provide 
reliable health-related information. Involving medical 
professionals in the care process, enhances infor-
mation provision through reliable information on 
drugs (eg, if users do not know how to behave in case 
of unexpected side effects). The fifth facilitator is 
‘Obtaining health-related feedback’. Feedback on 
health-related topics, in form of motivational mes-
sages, adjustment of a treatment plan, or treatment 
progress notifications, is supported by many mobile 
health IS offerings and gives users insight into their 
personal state of health. User-focused feedback on 
                                                 
1 The original taxonomy of health IT and medication adherence 
identified seven dimensions (drug adherence facilitators). Howev-
er, for this study six facilitators were used since ‘information stor-
age’ was not consistently interpreted by study participants. 
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health-related issues relieves medical professionals 
from common requests. The sixth drug adherence 
facilitator is ‘Personalization’. Personalization of 
mobile health IS is, for example, often realized 
through the adjustment of font size, hiding unwanted 
content (eg, text sections or functions), or reorganiz-
ing content. Personalized mobile health IS offer tai-
lored information provision to users and reduce us-
ers’ effort for understanding the provided information 
by displaying only relevant information (eg, hiding 
dosage for children for childless adults). 
 
3.3. Quantitative Survey Phase 
 
The online survey questionnaire started with a de-
scription of the domain and a brief instruction for the 
participants. Participants were asked to rate features 
on five point Likert scales according to their per-
ceived importance (1=‘not important’, 5=‘very im-
portant’) and to select one or more drug adherence 
facilitators that may be positively impacted by the 
respective feature. Before finishing the survey, par-
ticipants were asked for demographics and given the 
opportunity to make suggestions for additional fea-
tures or drug adherence facilitators not addressed in 
the study. 
The survey was carried out in three batches at dif-
ferent times via the labor market Amazon Mechanical 
Turk (AMT) with one day in between each batch to 
avoid daytime, or worker characteristic biases. To 
avoid common method biases the items were formu-
lated in simple language, unfamiliar terms were de-
fined, examples were provided where necessary, and 
double-barreled questions were decomposed [41]. On 
the first and the second day, 50 survey participants 
were solicited. Survey results were reviewed after 
each batch. The advantage of AMT, compared with 
conventional survey designs, where participants must 
be acquired on a voluntary basis, motivated with 
gifts, vouchers, or payments, is that AMT offers easy 
access to a high number of potential participants. 
AMT is a common tool in behavioral research and 
study sample, sample quality, and sample domain can 
be tailored to the needs and requirements of a particu-
lar study [42]. The number of participants can flexi-
bly be set and is usually reached in a very short peri-
od of time (1 hour for 50 participants). Extant re-
search demonstrates that survey results with AMT 
participants have high reliability, and provide higher 
quality data than student or public online surveys [11, 
43–45]. Participants choose the tasks they want to 
perform. Payment depends on the complexity and 
duration of the task and can be freely defined. In total 
we paid each study participant US$1.20 for the com-
pletion of the survey. We paid participants US$1.0 
for completing the survey. Furthermore, we paid an 
additional US$0.20 because we solicited only experi-
enced participants who had previously completed at 
least 5,000 tasks with an approval rate of 99% to en-
sure high data quality [46].  
 
4. Results 
 
4.1. Qualitative Survey Phase 
 
Overall twelve participants were interviewed 
(6=male, 6=female) with an average age of 35 years 
(min. age=20, max. age=50). In total, 90 desired fea-
tures were elicited. After removal of duplicates and 
features irrelevant for drug information provision (eg, 
finding medical professionals, price search engine for 
drugs), 33 features remained, and were classified in 
four groups: ‘Information provision features’ (INFO), 
‘Graphical user interface features’ (GUI), ‘Search 
and sort features’ (SEARCH), and ‘Features provid-
ing additional functionality’ (FUNC) (cf. Table 1).  
 
4.2. Quantitative Survey Phase 
 
Overall 208 U.S. participants responded to the sur-
vey. Each worker could only participate once in the 
survey. 18 participants (9%) aborted the survey, 20 
(10%) were excluded because of wrong control an-
swers, too short survey response time (under 
3 minutes for a 10-minute survey), and suspicious 
answer schemes (eg, same value for all features). 168 
(81%) participants completed the online survey 
(89=male, 79=female) with age between 20 and 64 
years. 60 (36%) participants were younger than 30 
years, 53 (32%) participants were between 30 and 39 
years old, 36 (21%) participants were between 40 and 
49 years old, 17 (10%) participants were between 50 
and 59 years old, and 2 (1%) participants were over 
60 years old. 87 (52%) participants had a university 
degree, 55 (33%) participants had a vocational- (24; 
14%), a secondary- (17; 10%), or a general- (14; 8%) 
school degree, 9 (5%) had an international Baccalau-
reate, 8 (5%) finished school with no qualification, 6 
(4%) were still in school, and 1 MBA-, 1 Associate’s-
, and 1 J.D. degree. Most of the participants (103; 
61%) were employed, 40 (24%) were self-employed, 
11 (7%) were unemployed, 7 (4%) were university 
students, 2 (1%) civil servants, 2 (1%) retired, and 3 
(2%) participants were on disability insurance. 
Overall participants gave positive response values 
on importance (mean across all features=3.80, min. 
mean=2.79, max. mean=4.6, 95% confidence inter-
val=0.06). Table 1 lists the elicited features from the 
quantitative study phase, ordered by mean im-
portance and perceived associations with drug
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Table 1. Desired features for drug information provision in health IS. 
 
Importance Perceived associations with drug 
adherence facilitators: n (%) 
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Rank / Feature 
1 FUNC: Check drugs for adverse drug reactions. 4.60 5.0 0.75 15 (05) 13 (05) 61 (22) 94 (33) 62 (22) 38 (13) 
2 GUI: Well-arranged presentation of drug information (eg, clear 
emphasis of headings, good structure and readability). 
4.58 5.0 0.68 59 (22) 17 (06) 48 (18) 63 (24) 49 (19) 28 (11) 
3 SEARCH: Search drugs by name. 4.42 5.0 0.86 96 (36) 19 (07) 35 (13) 42 (16) 34 (13) 41 (15) 
4 GUI: Display dosage information based on other factors than age 
(eg, weight, height, vital values). 
4.17 4.5 1.00 23 (08) 8 (03) 57 (20) 84 (29) 36 (13) 77 (27) 
5 GUI: Simple user interface design. 4.09 4.0 0.88 98 (32) 37 (12) 39 (13) 36 (12) 41 (13) 59 (19) 
6 INFO: Provide information whether a drug unit can be split. 4.08 4.0 0.99 16 (06) 17 (07) 51 (21) 79 (32) 39 (16) 45 (18) 
7 GUI: Display dosage information for a drug in different units (for 
example: ml, mg, g, cl, pills). 
4.06 4.0 1.04 30 (11) 10 (04) 51 (19) 88 (33) 29 (11) 55 (21) 
8 FUNC: Compare two or more drugs (eg, side-effects). 4.06 4.0 0.92 31 (12) 12 (05) 54 (22) 66 (26) 44 (18) 43 (17) 
9 SEARCH: Search drugs by application area/medical condition. 4.04 4.0 0.94 63 (25) 19 (08) 49 (19) 52 (21) 34 (13) 36 (14) 
10 INFO: Provide information on drugs which may be taken to 
alleviate side effects. 
4.03 4.0 0.97 16 (06) 10 (04) 63 (23) 71 (26) 66 (24) 48 (18) 
11 INFO: Provide information on how to enhance the effect of a 
taken drug (eg, through diet or specific behavior). 
3.98 4.0 0.91 13 (05) 13 (05) 47 (20) 55 (23) 54 (23) 57 (24) 
12 SEARCH: Filter and search for side-effects (eg, by occurrence). 3.98 4.0 1.01 47 (16) 17 (06) 51 (17) 58 (20) 50 (17) 72 (24) 
13 INFO: Provide information if a drug can be dissolved in a fluid. 3.98 4.0 1.02 14 (06) 10 (04) 49 (21) 71 (31) 39 (17) 49 (21) 
14 SEARCH: Filter search results by users' personal characteristics 
(eg, based on age, allergies, or personal preferences). 
3.96 4.0 1.09 57 (19) 13 (04) 48 (16) 45 (15) 44 (14) 101 (33) 
15 FUNC: Provide the possibility to store drugs users are taking. 3.92 4.0 1.16 55 (19) 18 (06) 43 (15) 43 (15) 42 (15) 86 (30) 
16 FUNC: Provide a tutorial on how to use the application. 3.91 4.0 1.03 47 (23) 17 (08) 31 (15) 32 (16) 23 (11) 52 (26) 
17 INFO: Provide information how a drug acts in your body. 3.90 4.0 0.97 12 (05) 12 (05) 41 (18) 54 (23) 65 (28) 48 (21) 
18 FUNC: Provide the ability to store users' personal information 
(eg, age, weight, allergies). 
3.87 4.0 1.12 71 (23) 14 (04) 37 (12) 41 (13) 41 (13) 111 (35) 
19 SEARCH: Search drugs by active ingredient. 3.80 4.0 1.05 59 (25) 19 (08) 41 (18) 53 (23) 28 (12) 32 (14) 
20 FUNC: Allow users to comment on their experiences with a drug. 3.80 4.0 1.08 31 (10) 10 (03) 75 (24) 33 (11) 75 (24) 83 (27) 
21 INFO: Provide additional information for the technical terms or 
abbreviations (eg, links to explanations, dictionaries, synonyms). 
3.76 4.0 1.12 23 (11) 12 (06) 45 (21) 63 (29) 45 (21) 27 (13) 
22 FUNC: Provide functionality to identify drugs (eg, shape, color). 3.75 4.0 1.07 38 (19) 10 (05) 33 (16) 61 (30) 33 (16) 29 (14) 
23 INFO: Provide information on follow-up drugs (eg, after the 
maximum application period of a drug exceeded). 
3.73 4.0 1.00 15 (06) 9 (04) 66 (28) 65 (27) 52 (22) 32 (13) 
24 FUNC: Provide functionality to print out selected information. 3.67 4.0 1.12 36 (18) 21 (11) 26 (13) 37 (19) 31 (16) 49 (25) 
25 FUNC: List all other drugs with same active ingredient as cur-
rently displayed drugs (eg, generic drugs). 
3.64 4.0 1.08 21 (09) 17 (07) 62 (27) 66 (29) 31 (14) 31 (14) 
26 SEARCH: Search drugs by a unique local identifier (eg, NDC, 
PZN, UDI). 
3.57 4.0 1.24 83 (33) 22 (09) 41 (16) 44 (17) 30 (12) 33 (13) 
27 SEARCH: Filter for requirement of prescription. 3.55 4.0 1.09 53 (21) 13 (05) 53 (21) 47 (19) 31 (12) 57 (22) 
28 FUNC: List all other drugs for the same application area/medical 
condition as currently displayed drugs. 
3.40 3.5 1.12 22 (10) 11 (05) 61 (29) 59 (28) 32 (15) 26 (12) 
29 GUI: Integrate images/pictograms to illustrate drug information. 3.24 3.0 1.12 30 (16) 14 (08) 24 (13) 34 (18) 32 (17) 50 (27) 
30 SEARCH: Search drugs by company/manufacturer. 3.23 3.0 1.22 65 (30) 20 (09) 35 (16) 46 (21) 22 (10) 28 (13) 
31 FUNC: Provide image of drug package. 3.06 3.0 1.18 22 (14) 13 (08) 19 (12) 54 (34) 17 (11) 34 (21) 
32 INFO: Provide information on homespun remedies. 2.86 3.0 1.35 10 (06) 10 (06) 33 (19) 27 (16) 37 (21) 56 (32) 
33 GUI: Customizable user interface. 2.79 3.0 1.25 33 (13) 25 (10) 25 (10) 14 (05) 21 (08) 144 (55) 
Average and total values: 3.80 3.9 1.94 1304 
(16%) 
502 
(06%) 
1494 
(18%) 
1777 
(22%) 
1309 
(16%) 
1757 
(22%) 
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adherence facilitators. Based on these results, the 
derived features were classified into three groups: 
‘Essential features’, ‘Nice-to-have features’, and 
‘Convenience features’ (cf. Figure 1). Essential fea-
tures (4 items) were rated most important for drug 
information provision mobile health IS. Nice-to-have 
features (23 items) represent the class of context-
specific features, that may be irrelevant for some user 
groups but advantageous for other users (eg, a tutorial 
on app usage may be superfluous by experienced 
users but desired for unexperienced users). Conven-
ience features (6 items) are features with the lowest 
importance ratings, these features may offer useful 
functionality for some users of mobile drug adher-
ence health IS. Figure 1 shows the breakdown by 
average feature rating in groups.  
Most features facilitate drug adherence through 
‘Quality control by medical professionals’ and ‘Per-
sonalization’ (both 22%). At the end of the study, 
participants were asked to comment on the study or 
to propose features, which were not elicited in the 
first phase of our study. Most participants (130; 77%) 
ignored the free text field or noted, that the amount of 
features leaves nothing more to expect. However, 38 
participants responded with detailed feedback on the 
study and detailed feature descriptions for mobile 
drug provision health IS. A noticeable amount of 
feedback is concerned with demand for a feature es-
tablishing communication between care-providers or 
pharmacists and patients. For instance, survey partic-
ipants stated: 
“I did feel the option to see other users’ feed-
back/opinions would be incredibly valuable.” 
“Ability to communicate with a doctor” 
“I might add some kind of functionality to allow 
the user to get in contact with a pharmacist.” 
We selectively address further constructive an-
swers in the discussion section. A complete list of 
participants’ feedback as well as the complete survey 
results is available from the authors upon request. 
 
5. Discussion 
 
This study investigates features desired by users 
for drug information provision through mobile health 
IS. It is apparent from the qualitative survey phase 
that users are mostly interested in features enabling 
them to refine provided drug information and to 
quickly find certain information (eg, drug infor-
mation on alternative or similar drugs for the same 
application area). Demand for personalization or in-
dividualization of the provided drug information is 
lower. Refinement and personalization features can 
both enable patients to tailor provided drug infor-
mation to their needs and demands. Previous research 
discovered that provided drug information usually 
exceeds the amount of information required by pa-
tients [20]. Hence, patients demand features that ena-
ble them to hide unwanted or irrelevant information 
or to enrich the provided information with explana-
tions or additional information [47].  
Results of the quantitative survey phase demon-
strate that features for adverse drug reaction check, 
search features, and well-arranged drug information 
presentation are the most desired features. This is 
also supported by extant research in the domain of 
clinical pharmacology [48]. Features like search 
drugs by manufacturer (#30), show image of a drug 
package (#31), show information on homespun rem-
edies (#32), and customization of the graphical user 
interface (#33) are the least desired features. Howev-
er, these features also received high importance rat-
ings by several survey participants (29 (17%), 21 
(13%), 25 (15%), and 19 (11%) participants gave the 
highest possible rating, respectively). These results 
indicate that users may underestimate the riskiness of 
features. Features #32 and #33 may, for example, 
bear risks by providing dangerous information (eg, 
ineffective homespun remedies [49]) or through acci-
dental hiding of relevant information on drugs 
through wrong personalization preferences.  
When it comes to seeking health information 
online, most users are motivated by an illness or a 
problematic situation [50]. Users search for infor-
mation helping them to make the right decisions to 
solve the problem. Uncontrollable problems, in par-
ticular uncontrollable health problems attributed to 
wrong drug application, may cause serious harm to 
users’ state of health [4, 51]. Hence, users want to 
receive the desired information, and to take action 
quickly. Our survey supports these findings by a low 
demand for the feature: “Customizable user inter-
face.” (#33, mean=2.79) (cf. Table 1). Users expect 
easy-to-use user interfaces without or with little setup 
effort, which for instance, two participants explicitly 
requested: 
“Other than making it easy to find info on medi-
cations, no.” 
“Just make it as easy to use as possible. […] they 
[people] can be easily confused.” 
Furthermore, survey participants mentioned that 
they prefer information whether drugs are covered by 
users’ health insurance. For instance, one survey par-
ticipant stated: 
„Also would it be possible (or impossible!) to 
load insurance information such as co-pays, de-
ductibles, coinsurance, etc. by insurance provid-
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er, so that a US patient would be able to know if 
they could afford to take the medicine or not? “ 
The quantitative survey phase reveals associated drug 
adherence facilitators for each feature but also gives a 
general overview of most often associated facilitators 
over all features. Overall, the most influential drug 
adherence facilitators for the analyzed features are: 
‘Quality control by medical professionals’ (22%), 
‘Personalization’ (22%), and “Collaboration with 
medical professionals or users” (18%) (cf. Table 1). 
Extant research supports our findings on usefulness 
of social support for patients to find relevant infor-
mation in social networks [52]. Since features foster-
ing communication between medical professionals or 
other users were not included in our survey, many 
survey participants explicitly mentioned to consider 
these features (cf. Section 4.2). 
In contrast to the qualitative phase, where user in-
terface personalization features were frequently men-
tioned in personal interviews, our findings from the 
quantitative phase reveal the exact opposite. Users 
expect personalization features only for the provided 
drug information, which would result in lower effort 
to obtain the demanded information. These findings 
are supported by high ratings for personalization fea-
tures (#4, mean=4.17; #14, mean=3.96) and by par-
ticipants’ responses in the open text answer section of 
the survey. For instance, two participants stated: 
“A personal journal section where users can 
write down their experiences […] can be helpful 
to keep track of how effective certain treatments 
on a personal basis. The patient could easily 
track their thoughts, benefits, and side-effects of 
each medication they are taking in one place 
online.” 
“[…] Most [features] were geared towards per-
sonalization.” 
Many features, frequently mentioned in the quan-
titative survey and highly demanded by patients in 
the quantitative study are not offered in today’s mo-
bile health IS landscape. In the qualitative survey 
phase, participants often mentioned features, that 
allow to check for adverse drug reactions or to com-
pare drugs (eg, by side-effects). In the quantitative 
phase, importance of these features for patients was 
confirmed through high ratings (#1, mean=4.6; #8, 
mean=4.06). These results indicate, that patients need 
information on drug compatibility and on negative 
consequences when taking specific drugs. In contrast, 
mobile health IS offerings available today seem ra-
ther focus on covering many platforms to offer their 
features to patients (eg, availability of apps offering 
features to improve drug adherence on multiple mo-
bile OS platforms) or the implementation of fancy 
technologies (eg, cloud computing features) fostering 
location and device independent access to infor-
mation. In our study, the drug adherence facilitator: 
“Location- and device independent access” is least 
often associated with features for drug information 
provision, which indicates patients’ unawareness or 
lack of interest for features enabling patients to store 
personal drug information in cloud services or ac-
cessing them with different devices. Furthermore, 
extant research results reveal a demand for mobile 
health IS offering a wide range of features and en-
hanced levels of functionality [9]. Our study results 
reveal that patients find only a small set of features 
very important. Additional features could be added to 
target specific patient groups and diversify offered 
mobile health IS. Offering functionality for a desig-
nated interest group or domain could meet expecta-
tions more effectively, reduces sources for errors, and 
offers greater benefit for users. This would also entail 
easier system design due to a smaller set of features 
to develop, to test, and to maintain and purposeful 
attention to specific needs of a specific group of us-
ers. 
Our study provides insights on the relative im-
portance of drug information provision features for 
users but does not provide insights on other interest 
groups in health care. Hence, future research should 
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Figure 1. Mean importance values for all features. (Vert.-axis: Mean importance; Hor.-axis: Feature #) 
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investigate whether and how the identified features 
are important to medical professionals, pharmacists, 
and vendors. Given that desired features are highly 
dependent on factors such as experiences or disease 
patterns, evaluating expected features under different 
contextual conditions or comparing expectations of 
different health care interest groups seem to be prom-
ising research directions. Furthermore, it is unclear 
whether features demanded by patients, can be bene-
ficial for patients and improve patients drug adher-
ence. After careful elaboration and design, the effica-
cy of these features must be tested and established in 
real world settings (eg, with a clinical trial). 
Limitations of our study affect the following as-
pects. First, although our sample size for the qualita-
tive phase (12 respondents) is sufficient to provide an 
estimate of patients desired features, it is relatively 
small. A larger sample size may include further user 
groups and identify further desired features. Second, 
the quantitative study is limited to one country. 
Hence, a larger sample might incorporate perspec-
tives from different countries with different health 
care expectations. Third, the quantitative survey was 
carried out via the labor market AMT with a partici-
pants group restricted to the U.S. Different sampling 
strategies may lead to different results. Furthermore, 
inclusion of international participants from other re-
gions than the U.S., might also lead to different fea-
ture ratings and overall different survey outcomes. A 
larger sample size would also allow to account for 
differences in financial status and insurance situation. 
A promising opportunity would be to explore users’ 
expectations for features for drug information provi-
sion across cultures. Fourth, our research only con-
siders users’ expectations for features for drug infor-
mation provision. We did not cover features that us-
ers’ do not want in drug information provision apps, 
which might reveal different insights. Furthermore, 
features appearing important in the qualitative survey 
phase, turned out not important in the quantitative 
study phase (eg, interface personalization), which 
indicates that patients’ demands may vary due to var-
ious reasons. Features may seem important on paper 
but are perceived as unimportant when implemented. 
The results of our research contribute to the de-
velopment of patient-centered mobile health IS. Iden-
tifying patients’ demands and preferences for mobile 
health IS features and implementing these in ‘ready-
to-use’ mobile health IS offerings promotes patient 
involvement, participation and empowerment. Design 
and development of mobile health IS targeting drug 
adherence in form of mobile apps based on patients’ 
ideas and beliefs might lead to more frequent use. 
This may in turn lead to higher effectiveness of these 
apps and improve health care outcomes. 
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